Galapagos: Filgotinib remains a strong asset, whether on a standalone basis or in partnership

BUY, Fair Value EUR50 vs.61 (+11%)
News published on September Monday 28, 2015
Share on

AbbVie released phase II top-line results for its KJAK inhibitor ABT-494 which met primary endpoint. In the meantime, the company announced it is to terminate the partnership agreement it had with GLPG as it will move its own programme in phase III. We believe that filgotinib has a significant potential in the RA space and that a partnership should be inked shortly.

For more information, please contact 

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities